GVK BIO in Trouble
|
Case Code: BSTR488 Case Length: 10 Pages Period: 2014-2015 Pub Date: 2016 Teaching Note: Not Available |
Price: Rs.500 Organization: GVK BIO Industry: Pharmaceutical Industry Countries: India Themes: Business, Operational Strategy, Management |
Abstract Case Intro 1 Case Intro 2 Excerpts
Abstract
This case is about the problems faced by India-based pharmaceutical research company GVK BIO due to the ban imposed by the European Union (EU) suspending sales and distribution of around 700 generic drugs being sold by various global pharma companies for which clinical trials were conducted at the GVK BIO facility in Hyderabad. The case focuses on the alleged manipulation of clinical trials at GVK Bio. It concludes by discussing the impact of the ban on the reputation of GVK BIO and how winning back the trust of global regulators would be a tough task for GVK BIO going forward.
Issues
The case is structured to achieve the following teaching objectives:
- Understand the importance of clinical trials in the drug discovery process
- Understand the implications of the EU ban on GVK BIO’s business
- Explore ways in which GVK BIO can salvage its reputation and the measures it has to take to improve transparency in clinical trials
Contents
-
Introduction
About GVK BIO
Clinical Trials in India
GVK BIO Enters Clinical Trials
The EU Ban
The Aftermath
The Road Ahead
Exhibits
Keywords
GVK BIO, Clinical trials, Drug discovery, Pharmaceutical industry, Generic drugs, Contract Research Organization, European Union ban, European Medicines Agency (EMA)
Buy this case study (Please select any one of the payment options)
| Price: Rs.500 |
Price: Rs.500 | PayPal (11 USD) |
